![]()
Béa, the virtual fertility clinic behind the FDA-cleared Béa Applicator, today launched OBGYN-prescribed ovulation medication in all 50 states. Patients can now add letrozole, an oral ovulation medication, to their at-home Béa insemination cycle, or take it on its own. A licensed OBGYN reviews every patient and prescribes only when it’s clinically appropriate, and a Béa fertility nurse guides the patient through every cycle.
The launch makes Béa the first company to deliver medicated intracervical insemination (ICI) at home, with clinical oversight at every step. Medicated cycles have historically meant clinic visits, scans and blood tests. Béa now delivers the medication, the device and the care team to the patient’s door.
Most U.S. insurers won’t cover fertility testing or IVF until women under 35 have tried for a year. Clinic cycles cost about $1,363 for IUI and $23,474 for IVF. Béa’s medicated cycles start at $298, with no referral, waitlist or clinic visit.
The launch allows Bea to better serve people with PMOS (PCOS) or irregular cycles who don’t ovulate reliably on their own. Letrozole helps the body release an egg on time, and the Béa Applicator places sperm directly at the cervix, delivering 3.23 times more sperm to the cervix than intercourse. Together, they give patients a guided, clinically backed option before IUI or IVF.
The process runs entirely online:
- Medical questionnaire. Patients complete it after purchase. No in-person or virtual appointment required.
- OBGYN review. A licensed OBGYN from Béa’s prescribing partner reviews the questionnaire, usually within 24 hours, and prescribes only if letrozole is right for the patient. Patients who aren’t prescribed are refunded in full, minus a $25 processing fee.
- Pharmacy dispensed medication. Letrozole ships from a licensed U.S. pharmacy, separately from the Béa kit.
- Nurse-guided care. Every patient starts with a pre-treatment call with a Béa fertility nurse, then texts that same nurse throughout the cycle.
“For most people, the first year of trying is a year of being told to wait,” said Tess Cosad, Founder and CEO of Béa. “Medicated cycles were one of the most effective tools a clinic could offer, and they were locked behind referrals, waitlists and exam rooms. We’ve spent four years building an insemination treatment that works at home. Adding prescribed medication means more people can take real clinical action from month one, on their own timeline.”
“Letrozole is a well-established first-line option for supporting ovulation, particularly for patients with PMOS (formerly known as PCOS),” said Dr. Charlotte Hastings, OBGYN at Dartmouth Health and Béa Clinical Advisor. “Pairing it with intracervical insemination and consistent nurse follow-up gives patients a structured, supervised cycle at home, with a clinician reviewing whether it’s appropriate before anything is prescribed.”
Every plan includes fertility nurse support, discreet delivery and interest-free installments, and is HSA/FSA eligible. Patients can check eligibility with a free two-minute assessment at beafertility.com.
About Béa
Béa is a virtual fertility clinic that combines expert-led care with medical-grade at-home technology to support people through the earliest stages of trying to conceive. After four years of R&D, Béa redesigned intracervical insemination, a treatment fertility clinics have used for decades, into the Béa Applicator, an FDA-cleared Class II medical device used at home. Béa patients can add letrozole, an oral ovulation medication prescribed by a licensed OBGYN when appropriate, and are supported by a dedicated fertility nurse throughout every cycle. Solo or partnered, Béa supports every path to parenthood.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261117980916/en/
Media gallery